An optimized oncolytic SeV vector, in which replacement of the trypsin cleavage site of F protein for a urokinase type plasminogen activator (uPA)-sensitive sequence has been generated, showed significant potential to target urokinase-expressing cancers, such as pancreatic cancer. The gene discussed is PLAU; the disease is cancer.